Ads
related to: biogen tecfidera- GA Mechanism of Action
Learn More About How
Glatiramer Acetate Works
- View Savings and Support
Learn More About Patient Access
and Other Support Options
- GA Mechanism of Action
Search results
Biogen holds onto Tecfidera market in Europe for a little longer
BioPharma Dive via Yahoo Finance· 5 months agoA decision by European regulators to revoke approvals for five generic versions of Biogen's multiple...
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks via Yahoo Finance· 1 month agoBiogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key...
Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have lost about...
Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue
Investor's Business Daily· 3 months agoBiogen's turnaround is still a "work in progress," an analyst said Tuesday as Biogen stock slumped...
Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout
Investor's Business Daily· 7 months agoBiogen stock skidded Wednesday on a "low-quality" sales beat that relied on other revenue. But...
Biogen Skids Despite Beat-And-Raise Quarter As Pressure Builds In Alzheimer's Market
Investor's Business Daily· 2 years agoBiogen stock toppled within a profit-taking zone Tuesday despite a beat-and-raise earnings report...
Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs
Zacks via Yahoo Finance· 1 year agoBiogen BIIB reported first-quarter 2023 adjusted earnings per share (EPS) of $3.40, beating the...
Biogen's Quarterly Report Was 'Fine' — Here's Why Shares Toppled
Investor's Business Daily· 2 years agoBiogen's second-quarter report was "fine," according to one analyst. But without an update on its...
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook
Zacks via Yahoo Finance· 2 years agoBiogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as...
Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount
Investor's Business Daily· 1 year agoBiogen stock was hamstrung Wednesday on a mixed 2023 outlook that assumes expenses for new...
Ads
related to: biogen tecfidera
